Next Article in Journal
Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance
Previous Article in Journal
Targeting Oncogenic BRAF: Past, Present, and Future
Open AccessReview

Targeting Heat Shock Protein 27 in Cancer: A Druggable Target for Cancer Treatment?

Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul 03760, Korea
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(8), 1195; https://doi.org/10.3390/cancers11081195
Received: 3 July 2019 / Revised: 6 August 2019 / Accepted: 7 August 2019 / Published: 16 August 2019
Heat shock protein 27 (HSP27), induced by heat shock, environmental, and pathophysiological stressors, is a multi-functional protein that acts as a protein chaperone and an antioxidant. HSP27 plays a significant role in the inhibition of apoptosis and actin cytoskeletal remodeling. HSP27 is upregulated in many cancers and is associated with a poor prognosis, as well as treatment resistance, whereby cells are protected from therapeutic agents that normally induce apoptosis. This review highlights the most recent findings and role of HSP27 in cancer, as well as the strategies for using HSP27 inhibitors for therapeutic purposes. View Full-Text
Keywords: heat shock protein 27; HSP27 inhibitor; anti-cancer drugs; resistance heat shock protein 27; HSP27 inhibitor; anti-cancer drugs; resistance
Show Figures

Figure 1

MDPI and ACS Style

Choi, S.-K.; Kam, H.; Kim, K.-Y.; Park, S.I.; Lee, Y.-S. Targeting Heat Shock Protein 27 in Cancer: A Druggable Target for Cancer Treatment? Cancers 2019, 11, 1195.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop